vs
Side-by-side financial comparison of Beta Bionics, Inc. (BBNX) and STEM, INC. (STEM). Click either name above to swap in a different company.
STEM, INC. is the larger business by last-quarter revenue ($47.1M vs $27.6M, roughly 1.7× Beta Bionics, Inc.). STEM, INC. runs the higher net margin — -33.9% vs -79.3%, a 45.4% gap on every dollar of revenue. On growth, Beta Bionics, Inc. posted the faster year-over-year revenue change (56.6% vs -15.6%).
Beta Bionics, Inc. is a medical technology company focused on developing and commercializing advanced automated diabetes management solutions. Its core product is the iLet Bionic Pancreas, a wearable device that automatically adjusts insulin and glucagon delivery for people with Type 1 and Type 2 diabetes, serving primarily the U.S. healthcare market with plans for global expansion.
StemCells, Inc. is a public biopharmaceutical company headquartered in Newark, California, that is developing purified human neural stem cells (HuCNS-SCs) in the hopes of treating central nervous system disorders and paralysis. StemCells' HuCNS-SCs have the ability to differentiate into the three main types of cells found in the central nervous system: neurons, astrocytes and oligodendrocytes.
BBNX vs STEM — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $27.6M | $47.1M |
| Net Profit | $-21.9M | $-16.0M |
| Gross Margin | 59.5% | 48.9% |
| Operating Margin | -47.4% | -17.7% |
| Net Margin | -79.3% | -33.9% |
| Revenue YoY | 56.6% | -15.6% |
| Net Profit YoY | 23.6% | 68.8% |
| EPS (diluted) | $-0.49 | $-4.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $27.6M | — | ||
| Q4 25 | $32.1M | $47.1M | ||
| Q3 25 | $27.3M | $38.2M | ||
| Q2 25 | $23.2M | $38.4M | ||
| Q1 25 | $17.6M | $32.5M | ||
| Q4 24 | — | $55.8M | ||
| Q3 24 | — | $29.3M | ||
| Q2 24 | — | $34.0M |
| Q1 26 | $-21.9M | — | ||
| Q4 25 | $-13.5M | $-16.0M | ||
| Q3 25 | $-14.2M | $-23.8M | ||
| Q2 25 | $-16.9M | $202.5M | ||
| Q1 25 | $-28.7M | $-25.0M | ||
| Q4 24 | — | $-51.1M | ||
| Q3 24 | — | $-148.3M | ||
| Q2 24 | — | $-582.3M |
| Q1 26 | 59.5% | — | ||
| Q4 25 | 59.0% | 48.9% | ||
| Q3 25 | 55.5% | 35.5% | ||
| Q2 25 | 53.8% | 33.4% | ||
| Q1 25 | 50.9% | 32.4% | ||
| Q4 24 | — | -4.4% | ||
| Q3 24 | — | 21.2% | ||
| Q2 24 | — | 27.6% |
| Q1 26 | -47.4% | — | ||
| Q4 25 | -50.2% | -17.7% | ||
| Q3 25 | -62.5% | -33.6% | ||
| Q2 25 | -85.5% | -34.8% | ||
| Q1 25 | -105.7% | -65.0% | ||
| Q4 24 | — | -84.4% | ||
| Q3 24 | — | -493.2% | ||
| Q2 24 | — | -1705.5% |
| Q1 26 | -79.3% | — | ||
| Q4 25 | -41.9% | -33.9% | ||
| Q3 25 | -52.1% | -62.2% | ||
| Q2 25 | -72.6% | 527.8% | ||
| Q1 25 | -162.5% | -76.9% | ||
| Q4 24 | — | -91.6% | ||
| Q3 24 | — | -506.3% | ||
| Q2 24 | — | -1712.6% |
| Q1 26 | $-0.49 | — | ||
| Q4 25 | $-0.16 | $-4.40 | ||
| Q3 25 | $-0.33 | $-2.84 | ||
| Q2 25 | $-0.39 | $-1.79 | ||
| Q1 25 | $-0.93 | $-0.15 | ||
| Q4 24 | — | $-15.29 | ||
| Q3 24 | — | $-18.24 | ||
| Q2 24 | — | $-71.81 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $199.5M | $48.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $271.2M | $-249.4M |
| Total Assets | $304.4M | $308.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $199.5M | — | ||
| Q4 25 | $219.1M | $48.9M | ||
| Q3 25 | $228.7M | $43.1M | ||
| Q2 25 | $249.7M | $40.8M | ||
| Q1 25 | $231.5M | $58.6M | ||
| Q4 24 | — | $56.3M | ||
| Q3 24 | — | $75.4M | ||
| Q2 24 | — | $89.6M |
| Q1 26 | $271.2M | — | ||
| Q4 25 | $287.6M | $-249.4M | ||
| Q3 25 | $294.8M | $-235.7M | ||
| Q2 25 | $301.6M | $-214.1M | ||
| Q1 25 | $313.8M | $-417.5M | ||
| Q4 24 | — | $-398.4M | ||
| Q3 24 | — | $-344.1M | ||
| Q2 24 | — | $-203.2M |
| Q1 26 | $304.4M | — | ||
| Q4 25 | $328.7M | $308.9M | ||
| Q3 25 | $330.0M | $362.6M | ||
| Q2 25 | $330.0M | $379.2M | ||
| Q1 25 | $338.0M | $405.1M | ||
| Q4 24 | — | $437.4M | ||
| Q3 24 | — | $537.8M | ||
| Q2 24 | — | $691.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $8.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-8.6M | $8.2M | ||
| Q3 25 | $-8.7M | $11.4M | ||
| Q2 25 | $-13.6M | $-21.3M | ||
| Q1 25 | $-20.0M | $8.5M | ||
| Q4 24 | — | $-14.7M | ||
| Q3 24 | — | $-9.4M | ||
| Q2 24 | — | $-11.9M |
| Q1 26 | — | — | ||
| Q4 25 | $-10.5M | — | ||
| Q3 25 | $-10.0M | — | ||
| Q2 25 | $-15.4M | — | ||
| Q1 25 | $-20.3M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | -32.8% | — | ||
| Q3 25 | -36.7% | — | ||
| Q2 25 | -66.2% | — | ||
| Q1 25 | -115.1% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 5.9% | — | ||
| Q3 25 | 4.7% | — | ||
| Q2 25 | 7.7% | — | ||
| Q1 25 | 1.9% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.11× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
